Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib

被引：4

作者：

Doi, Ayako ^{[1
]}

Kuboki, Yasutoshi ^{[1
,2
]}

Shitara, Kohei ^{[1
]}

Fukuoka, Shota ^{[1
]}

Bando, Hideaki ^{[1
]}

Okamoto, Wataru ^{[1
]}

Kojima, Takashi ^{[1
]}

Doi, Toshihiko ^{[2
]}

Ohtsu, Atsushi ^{[3
]}

Yoshino, Takayuki ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwanoha 6-5-1, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

CLINICAL COLORECTAL CANCER | 2017年 / 16卷 / 02期

关键词：

Chemotherapy; GI perforation mCRC; Regorafenib; VEGF; ENDOTHELIAL GROWTH-FACTOR; PHASE-3; TRIAL; TUMOR ANGIOGENESIS; DOUBLE-BLIND; BEVACIZUMAB; PLACEBO; FLUOROURACIL; MULTICENTER; COMBINATION; LEUCOVORIN;

D O I：

10.1016/j.clcc.2016.11.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Regorafenib is an oral multikinase inhibitor that targets multiple pathways, including vascular endothelial growth factor receptor, and improves the survival of patients with metastatic colorectal cancer (mCRC). Gastrointestinal (GI) perforation and fistula are well-recognized adverse events associated with agents that target the VEGF pathway, including bevacizumab. We report 5 cases of GI perforation or fistula formation during treatment with regorafenib. We identified 1 case of GI perforation (0.6%) and 4 cases of fistula formation (2.4%) among 170 patients with mCRC administered regorafenib in our hospital. In all 5 cases, GI perforation or fistula involved the residual tumor and were successfully treated with antibiotic therapy or surgery and recovered from these adverse events. It is important to recognize that GI perforation and fistula can occur in patients treated with regorafenib. (C) 2016 The Author(s). Published by Elsevier Inc.

引用

页码：E109 / E113

页数：5

共 28 条

[1] Regorafenib use as a possible cause of intestinal perforation [J].

Adenis, Antoine ;

Kotecki, Nuria ;

Decanter, Gauthier ;

Clisant, Stephanie ;

Penel, Nicolas .

ACTA ONCOLOGICA, 2013, 52 (08) :1789-1790

[2] Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer [J].

Azad, Nilofer ;

Dasari, Arvind ;

Arcaroli, John ;

Taylor, Gretchen E. ;

Laheru, Daniel A. ;

Carducci, Michael A. ;

McManus, Martine ;

Quackenbush, Kevin ;

Wright, John J. ;

Hidalgo, Manuel ;

Diaz, Luis A., Jr. ;

Donehower, Ross C. ;

Zhao, Ming ;

Rudek, Michelle A. ;

Messersmith, Wells A. .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :345-354

[3] Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Demetri, George D. ;

Reichardt, Peter ;

Kang, Yoon-Koo ;

Blay, Jean-Yves ;

Rutkowski, Piotr ;

Gelderblom, Hans ;

Hohenberger, Peter ;

Leahy, Michael ;

von Mehren, Margaret ;

Joensuu, Heikki ;

Badalamenti, Giuseppe ;

Blackstein, Martin ;

Le Cesne, Axel ;

Schoffski, Patrick ;

Maki, Robert G. ;

Bauer, Sebastian ;

Binh Bui Nguyen ;

Xu, Jianming ;

Nishida, Toshirou ;

Chung, John ;

Kappeler, Christian ;

Kuss, Iris ;

Laurent, Dirk ;

Casali, Paolo G. .

LANCET, 2013, 381 (9863) :295-302

[4] Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].

Dvorak, HF .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380

[5]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[6] Bevacizumab-Associated Fistula Formation in Postoperative Colorectal Cancer Patients [J].

Ganapathi, Asvin M. ;

Westmoreland, Tammy ;

Tyler, Douglas ;

Mantyh, Christopher R. .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2012, 214 (04) :582-588

[7] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

[8] Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Grothey, Axel ;

Van Cutsem, Eric ;

Sobrero, Alberto ;

Siena, Salvatore ;

Falcone, Alfredo ;

Ychou, Marc ;

Humblet, Yves ;

Bouche, Olivier ;

Mineur, Laurent ;

Barone, Carlo ;

Adenis, Antoine ;

Tabernero, Josep ;

Yoshino, Takayuki ;

Lenz, Heinz-Josef ;

Goldberg, Richard M. ;

Sargent, Daniel J. ;

Cihon, Frank ;

Cupit, Lisa ;

Wagner, Andrea ;

Laurent, Dirk .

LANCET, 2013, 381 (9863) :303-312

[9] Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J].

Hicklin, DJ ;

Ellis, LM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1011-1027

[10] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

← 1 2 3 →